Skip to main content

Parkinson's Disease News (Page 3)

Related terms: Parkinson's

No Link Found Between Migraines, Parkinson's Disease

FRIDAY, Aug. 23, 2024 – Women who suffer frequent migraines don’t have any increased risk of developing Parkinson’s disease, finds a new study that refutes earlier research. “These results are reass...

Migraine in Women Not Linked to Risk for Parkinson Disease

THURSDAY, Aug. 22, 2024 – Migraine is not associated with an increased risk for developing Parkinson disease (PD) among women, according to a study published online Aug. 21 in Neurology. Ricarda S....

Brain Implant Helps Tame Parkinson's for Easier Daily Living

MONDAY, Aug. 19, 2024 – A brain implant guided by AI could provide around-the-clock personalized care for people with Parkinson’s disease, a new study suggests. The implant uses AI to monitor a p...

FDA Approves Crexont (carbidopa and levodopa) Extended-Release Capsules for the Treatment of Parkinson’s Disease

BRIDGEWATER, N.J.--(BUSINESS WIRE) August 7, 2024 – Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has appro...

New Upright Scanner Tracks Brain Function While You Walk

FRIDAY, Aug. 9, 2024 – A wearable brain scanner could improve research into Parkinson’s disease, dementia and other debilitating disorders, new research shows. The brain scanner – called the A...

Dementia May Not Be as Common Among Parkinson's Patients as Thought

THURSDAY, Aug. 8, 2024 – Many people with Parkinson's disease may fear dementia as a common consequence of the disease. But new research suggests dementia is not inevitable with Parkinson's, and in...

Dementia May Occur Less Often, Develop Slower in Parkinson Disease Patients

WEDNESDAY, Aug. 7, 2024 – For patients with Parkinson disease (PD), dementia may occur less often or develop over a longer time period than previously thought, according to a study published online...

Fecal Microbiota Transplant No Aid for Parkinson Disease

FRIDAY, Aug. 2, 2024 – Fecal microbiota transplantation (FMT) is safe but does not offer clinically meaningful improvements for Parkinson disease (PD), according to a study published online July 29...

Risk of Parkinson Disease Heightened in People With Anxiety

MONDAY, July 22, 2024 – The risk of developing Parkinson disease (PD) is at least doubled in people with anxiety compared with those without, according to a study published in the July issue of...

Retired Rugby Players Face Risks for Dementia, CTE

THURSDAY, July 18, 2024 – Alix Popham played in two rugby World Cups and won a Six Nations Grand Slam before retiring in 2011 as a professional in the rough-and-tumble game. By 2020, he had already...

Could Contact Sports Raise Risks for a Parkinson's-like Disorder?

WEDNESDAY, July 17, 2024 – Autopsies of deceased boxers and pro football players have long confirmed that repeat head injuries can lead to a devastating brain condition known as chronic traumatic...

Structure, Function of Brain Connectome Tied to Gray Matter Atrophy in Parkinson Disease

MONDAY, July 8, 2024 – For patients with mild Parkinson disease (PD), the structural and functional architecture of the brain connectome is associated with progression of gray matter (GM) atrophy,...

Adamas Announces FDA Approval for Second Indication for Gocovri as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb. 1, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people...

FDA Approves Kynmobi (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes

MARLBOROUGH, Mass.--(BUSINESS WIRE) May 21, 2020 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved Kynmobi (apomorphine HCI)...

FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes

SAN DIEGO – April 27, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Ongentys (opicapone) 25 mg and 50...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

ropinirole, carbidopa / levodopa, levodopa, amantadine